Market revenue in 2023 | USD 1,352.7 million |
Market revenue in 2030 | USD 2,980.5 million |
Growth rate | 11.9% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Manufacturing, Contract Development |
Key market players worldwide | Eurofins Scientific SE, WuXi Biologics (Cayman) Inc, Catalent Inc, AGC Inc, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Holdings Corp, Samsung BioLogics, Rentschler Biopharma SE, Recipharm |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule drug substance cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 67% in 2023. Horizon Databook has segmented the China large molecule drug substance cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the more technologically advanced countries in Asia Pacific and contributes significantly to the region’s healthcare industry. Regulatory changes to enhance safe & effective usage and rapid development of drugs in China are expected to positively influence the market growth.
Several companies have started increasing the number of collaborations between industry players and OEMs in the country. OEMs in China tend to focus on leveraging services that help reduce product recalls and minimize the time taken for regulatory approvals.
For instance, in January 2022, Lonza entered into an agreement with HaemaLogiX Ltd for manufacturing of drug substances for its KappaMab, which is a lead multiple myeloma drug candidate. The manufacturing will commence at its new facility in Guangzhou, China.
Horizon Databook provides a detailed overview of country-level data and insights on the China large molecule drug substance cdmo market , including forecasts for subscribers. This country databook contains high-level insights into China large molecule drug substance cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account